Follow
David Bond
David Bond
Assistant Professor, The Ohio State University
Verified email at osumc.edu
Title
Cited by
Cited by
Year
Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma
MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ...
New England Journal of Medicine 386 (7), 629-639, 2022
3422022
Targeting BTK in CLL: beyond ibrutinib
DA Bond, JA Woyach
Current hematologic malignancy reports 14, 197-205, 2019
1192019
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ...
Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021
892021
Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era
JN Gerson, E Handorf, D Villa, AS Gerrie, P Chapani, S Li, LJ Medeiros, ...
Journal of Clinical Oncology 37 (6), 471-480, 2019
882019
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome
AS Kittai, DA Bond, B William, A Saad, S Penza, Y Efebera, K Larkin, ...
Blood Advances 4 (19), 4648-4652, 2020
682020
Second cancer incidence in CLL patients receiving BTK inhibitors
DA Bond, Y Huang, JL Fisher, AS Ruppert, DH Owen, EM Bertino, ...
Leukemia 34 (12), 3197-3205, 2020
672020
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
RW Merryman, L Castagna, L Giordano, VT Ho, P Corradini, A Guidetti, ...
Leukemia 35 (9), 2672-2683, 2021
592021
NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B …
AR Mato, WG Wierda, WZ Ai, IW Flinn, M Tees, MR Patel, K Patel, ...
Blood 140 (Supplement 1), 2329-2332, 2022
442022
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib
AS Kittai, C Miller, D Goldstein, Y Huang, LV Abruzzo, K Beckwith, ...
Blood, The Journal of the American Society of Hematology 138 (23), 2372-2382, 2021
442021
CAR T-cell therapy for B-cell lymphoma
N Denlinger, D Bond, S Jaglowski
Current problems in cancer 46 (1), 100826, 2022
422022
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
RW Merryman, RA Redd, T Nishihori, J Chavez, Y Nieto, JM Darrah, ...
Blood Advances 5 (6), 1648-1659, 2021
362021
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
P Torka, SK Kothari, S Sundaram, S Li, LJ Medeiros, EC Ayers, ...
Blood advances 4 (2), 253-262, 2020
342020
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis
JP Alderuccio, AJ Olszewski, AM Evens, GP Collins, AV Danilov, M Bower, ...
Blood advances 5 (14), 2852-2862, 2021
332021
Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure
EC Ayers, S Li, LJ Medeiros, DA Bond, KJ Maddocks, P Torka, ...
Cancer 126 (2), 293-303, 2020
322020
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study
AS Zayac, AM Evens, A Danilov, SD Smith, D Jagadeesh, LA Leslie, ...
Haematologica 106 (7), 1932, 2021
282021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
DA Bond, JM Switchenko, D Villa, K Maddocks, M Churnetski, AS Gerrie, ...
Blood advances 5 (23), 5179-5189, 2021
262021
Bias and racism teaching rounds at an academic medical center
Q Capers IV, DA Bond, US Nori
Chest 158 (6), 2688-2694, 2020
252020
Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: analysis of the phase III Belinda study
MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ...
Blood 138, LBA-6, 2021
222021
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy
DJ Landsburg, ME Hughes, A Koike, D Bond, KJ Maddocks, L Guo, ...
Blood Advances 3 (2), 132-135, 2019
202019
Relapsed mantle cell lymphoma: current management, recent progress, and future directions
DA Bond, P Martin, KJ Maddocks
Journal of Clinical Medicine 10 (6), 1207, 2021
192021
The system can't perform the operation now. Try again later.
Articles 1–20